论文部分内容阅读
目的:综合评价坎地沙坦酯(candesartan cilexetil)治疗轻、中度原发性高血压的有效性及安全性。方法:对17篇关于坎地沙坦酯与其他常用抗高血压药的随机双盲平行对照临床试验的中国论文进行合并效应量的Meta分析。结果:坎地沙坦酯单独用药时的合并有效率和不良反应发生率与对照药物组的差别均无显著性(P>0.05);坎地沙坦酯联合其他抗高血压药的合并有效率是其单独用药的3.67倍(95%CI:2.13～6.30),而不良反应发生率与单独用药组差异无显著性(P=0.37)。结论:坎地沙坦酯是一种安全有效的治疗我国轻、中度原发性高血压的药物,并且联合其他抗高血压药的疗效更为显著。
Objective: To evaluate the efficacy and safety of candesartan cilexetil in the treatment of mild to moderate essential hypertension. METHODS: A Meta-analysis of the combined effect of 17 randomized, double-blind, parallel controlled clinical trials of candesartan cilexetil and other commonly used antihypertensive agents was performed. Results: There was no significant difference between the two groups in the efficacy of candesartan cilexetil alone and in the control group (P> 0.05). The combined effective rate of candesartan cilexetil and other antihypertensive drugs 3.67 times (95% CI: 2.13-6.30) of the drug alone, but the incidence of adverse reactions was not significantly different from that of the drug alone group (P = 0.37). Conclusion: Candesartan cilexetil is a safe and effective treatment of mild and moderate essential hypertension in our country, and the combination of other antihypertensive drugs is more effective.